ACCESS Newswire·Feb 26, 2026, 4:15 PM ET

Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025

REVB

Revelation Biosciences reported financial results for the three and twelve months ended December 31, 2025.
The company announced positive results from its PRIME clinical study in late-stage chronic kidney disease patients.
An agreement with the FDA was reached for a single adaptive Phase 2/3 study to approve Gemini for acute kidney injury treatment.
Revelation received $6.7 million in net proceeds from a warrant inducement completed in January 2026.
Clinical data on Gemini's potential for acute kidney injury (AKI) and chronic kidney disease (CKD) will be presented at the International Conference on Advances in Critical Care Nephrology from March 29 to April 1, 2026.
Cash and cash equivalents increased to $10.7 million as of December 31, 2025, from $6.5 million in 2024, sufficient to fund operations into the first quarter of 2027.
Net cash used for operating activities for the twelve months ended December 31, 2025, was $8.3 million, compared to $18.3 million in the prior year.
The net loss for the year ended December 31, 2025, was $8.9 million, or $23.95 per share, compared to $15.0 million, or $1,052.16 per share, in 2024.
Gemini is a proprietary PHAD formulation acting as a TLR4 agonist currently in development for AKI, CKD, severe burn, and post-surgical infection indications.
The company has multiple ongoing clinical programs evaluating Gemini across acute kidney injury, chronic kidney disease, infection prevention, hyperinflammation reduction, severe burn treatment, and post-surgical infection prevention.